patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_983531 | REC_0001701 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 10.9 | 68 | female | 0 | 20 | 5.6 | 1 | pembrolizumab 200 mg q3w | 23.7 | true | MSS | 2026-03-15T05:35:57.263846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971662 | REC_0001702 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 22.8 | 47 | male | 0 | 15 | 5.2 | 7 | alectinib 600 mg BID | 14.7 | true | MSI-H | 2026-03-15T05:35:57.264115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899127 | REC_0001703 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.7 | 58 | male | 1 | 19 | 5.2 | 3 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.264363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317470 | REC_0001704 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 15.2 | 66 | female | 0 | 21 | 5.8 | 0 | osimertinib 80 mg daily | 25.2 | false | MSI-H | 2026-03-15T05:35:57.264656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852359 | REC_0001705 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.4 | 62 | male | 1 | 47 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.5 | false | MSS | 2026-03-15T05:35:57.264892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356050 | REC_0001706 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.7 | 56 | male | 0 | 13 | 3.5 | 4 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.265125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139112 | REC_0001707 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 4 | 77 | female | 2 | 36 | 6.4 | 6 | pembrolizumab 200 mg q3w | 16.1 | true | MSS | 2026-03-15T05:35:57.265359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133703 | REC_0001708 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.2 | 75 | female | 1 | 0 | 8 | 1 | alectinib 600 mg BID | 17.5 | true | MSS | 2026-03-15T05:35:57.265591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372342 | REC_0001709 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 8 | 81 | female | 1 | 15 | 6 | 5 | pembrolizumab 200 mg q3w | 9.4 | true | MSS | 2026-03-15T05:35:57.265819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459004 | REC_0001710 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 8.9 | 67 | female | 1 | 20 | 5.4 | 1 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.266043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973768 | REC_0001711 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.9 | 59 | female | 1 | 12 | 7 | 1 | entrectinib 600 mg daily | 21.3 | false | MSS | 2026-03-15T05:35:57.266278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895718 | REC_0001712 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 14 | 7.1 | 60 | female | 1 | 18 | 5.8 | 6 | pembrolizumab 200 mg q3w | 14.5 | false | MSS | 2026-03-15T05:35:57.266509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307983 | REC_0001713 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 17.4 | 66 | female | 0 | 19 | 6.2 | 8 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.266743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761941 | REC_0001714 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.6 | 60 | female | 1 | 15 | 4.6 | 4 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.266973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987376 | REC_0001715 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 5.9 | 71 | female | 2 | 6 | 7.8 | 6 | entrectinib 600 mg daily | 4.2 | true | MSS | 2026-03-15T05:35:57.267201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864050 | REC_0001716 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 15.3 | 68 | female | 0 | 4 | 6.2 | 1 | alectinib 600 mg BID | 15.2 | false | MSI-H | 2026-03-15T05:35:57.267431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411667 | REC_0001717 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.4 | 56 | male | 0 | 14 | 5.7 | 3 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:57.267709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542584 | REC_0001718 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 12.1 | 65 | female | 0 | 8 | 6.8 | 1 | osimertinib 80 mg daily | 22.6 | false | MSS | 2026-03-15T05:35:57.267949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502624 | REC_0001719 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.9 | 60 | female | 0 | 47 | 7.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:57.268233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414937 | REC_0001720 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.8 | 53 | female | 0 | 9 | 5.4 | 8 | pembrolizumab 200 mg q3w | 12.5 | true | MSS | 2026-03-15T05:35:57.268477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373692 | REC_0001721 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.2 | 72 | female | 2 | 20 | 3.5 | 7 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:57.268713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824571 | REC_0001722 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12 | 61 | male | 0 | 26 | 4.3 | 2 | alectinib 600 mg BID | 20.7 | false | MSI-H | 2026-03-15T05:35:57.268952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259077 | REC_0001723 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 15.8 | 68 | female | 1 | 8 | 2.8 | 2 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:57.269186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237599 | REC_0001724 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 33 | 12.9 | 68 | female | 1 | 10 | 6.4 | 0 | sotorasib 960 mg daily | 30.3 | true | MSS | 2026-03-15T05:35:57.269417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281609 | REC_0001725 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14.2 | 70 | female | 1 | 3 | 3.2 | 6 | entrectinib 600 mg daily | 18 | false | MSI-H | 2026-03-15T05:35:57.269648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122416 | REC_0001726 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.7 | 65 | female | 1 | 61 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:57.269877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285425 | REC_0001727 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.4 | 78 | female | 2 | 11 | 6.3 | 5 | alectinib 600 mg BID | 15.4 | false | MSI-H | 2026-03-15T05:35:57.270108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904879 | REC_0001728 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 16.9 | 71 | female | 2 | 15 | 4.2 | 5 | alectinib 600 mg BID | 12.1 | false | MSI-H | 2026-03-15T05:35:57.270340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992954 | REC_0001729 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.8 | 78 | male | 0 | 20 | 7.5 | 6 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:57.270575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901459 | REC_0001730 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.9 | 62 | male | 1 | 13 | 7.8 | 6 | sotorasib 960 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:57.270859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522204 | REC_0001731 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 16.6 | 57 | female | 0 | 12 | 7.4 | 2 | sotorasib 960 mg daily | 21 | true | MSI-H | 2026-03-15T05:35:57.271098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741390 | REC_0001732 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 11.8 | 67 | female | 1 | 27 | 3.9 | 4 | pembrolizumab 200 mg q3w | 11.9 | false | MSI-H | 2026-03-15T05:35:57.271328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848423 | REC_0001733 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 6.4 | 90 | male | 2 | 20 | 5.9 | 1 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:35:57.271562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163608 | REC_0001734 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 7 | 58 | male | 1 | 24 | 5.5 | 1 | pembrolizumab 200 mg q3w | 14.7 | false | MSS | 2026-03-15T05:35:57.271793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722658 | REC_0001735 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.8 | 70 | female | 3 | 10 | 7.5 | 6 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:57.272029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622287 | REC_0001736 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 12.7 | 65 | female | 1 | 14 | 6.6 | 1 | pembrolizumab 200 mg q3w | 26.5 | false | MSI-H | 2026-03-15T05:35:57.272307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515526 | REC_0001737 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10 | 61 | female | 0 | 24 | 6.2 | 1 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:57.272549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405163 | REC_0001738 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.7 | 69 | female | 1 | 19 | 6.6 | 5 | sotorasib 960 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:57.272777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863542 | REC_0001739 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 8.2 | 54 | male | 0 | 15 | 3.5 | 4 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.273013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254638 | REC_0001740 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9 | 75 | female | 1 | 16 | 4.5 | 9 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:35:57.273239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650190 | REC_0001741 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 9.4 | 64 | female | 0 | 40 | 3.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 4.1 | true | MSS | 2026-03-15T05:35:57.273469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894077 | REC_0001742 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 18 | 17.4 | 64 | male | 1 | 17 | 7 | 0 | alectinib 600 mg BID | 53.9 | false | MSI-H | 2026-03-15T05:35:57.273706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690493 | REC_0001743 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 15.7 | 63 | female | 0 | 12 | 6.2 | 0 | alectinib 600 mg BID | 23.2 | false | MSI-H | 2026-03-15T05:35:57.273985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973018 | REC_0001744 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.1 | 65 | male | 0 | 16 | 4.3 | 7 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:35:57.274219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584692 | REC_0001745 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 9.4 | 68 | female | 1 | 15 | 5 | 1 | sotorasib 960 mg daily | 25.1 | true | MSS | 2026-03-15T05:35:57.274447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174489 | REC_0001746 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 28 | 5.1 | 58 | female | 1 | 54 | 4.7 | 0 | pembrolizumab 200 mg q3w | 45 | true | MSS | 2026-03-15T05:35:57.274677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284927 | REC_0001747 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.9 | 64 | female | 0 | 48 | 4.3 | 7 | pembrolizumab 200 mg q3w | 17.6 | false | MSS | 2026-03-15T05:35:57.274910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511160 | REC_0001748 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 8 | 69 | female | 1 | 8 | 4.7 | 2 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:57.275137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582975 | REC_0001749 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 12.2 | 59 | male | 1 | 10 | 3.1 | 0 | alectinib 600 mg BID | 29.8 | true | MSI-H | 2026-03-15T05:35:57.275372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262207 | REC_0001750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.2 | 63 | male | 0 | 15 | 6.2 | 5 | alectinib 600 mg BID | 13 | false | MSI-H | 2026-03-15T05:35:57.275605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982952 | REC_0001751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.4 | 81 | male | 1 | 13 | 5.4 | 1 | alectinib 600 mg BID | 23.6 | false | MSS | 2026-03-15T05:35:57.275836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165081 | REC_0001752 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.4 | 71 | female | 2 | 54 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:35:57.276062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589945 | REC_0001753 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 16.9 | 60 | male | 1 | 11 | 5.8 | 5 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:57.276333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103089 | REC_0001754 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.9 | 71 | male | 1 | 16 | 6.5 | 4 | entrectinib 600 mg daily | 13 | true | MSS | 2026-03-15T05:35:57.276577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411702 | REC_0001755 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.2 | 48 | male | 0 | 18 | 6 | 5 | sotorasib 960 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:57.276820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288259 | REC_0001756 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12 | 71 | male | 0 | 10 | 3.4 | 6 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.277109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553743 | REC_0001757 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.5 | 70 | female | 2 | 16 | 6.6 | 6 | pembrolizumab 200 mg q3w | 6.6 | true | MSS | 2026-03-15T05:35:57.277339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582377 | REC_0001758 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.3 | 68 | female | 0 | 74 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:35:57.277573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293703 | REC_0001759 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.9 | 68 | female | 1 | 21 | 7.2 | 1 | osimertinib 80 mg daily | 29.7 | true | MSS | 2026-03-15T05:35:57.277808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916722 | REC_0001760 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 10.3 | 60 | female | 1 | 12 | 5.1 | 1 | osimertinib 80 mg daily | 26.1 | true | MSS | 2026-03-15T05:35:57.278042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283394 | REC_0001761 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.3 | 67 | male | 0 | 5 | 5.7 | 1 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.278274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224564 | REC_0001762 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 10.8 | 64 | female | 0 | 16 | 6.3 | 3 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:35:57.278509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547731 | REC_0001763 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 10.5 | 57 | male | 1 | 9 | 5.1 | 3 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:57.278751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199423 | REC_0001764 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.9 | 59 | female | 0 | 1 | 7.2 | 9 | alectinib 600 mg BID | 14.4 | false | MSI-H | 2026-03-15T05:35:57.278998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918140 | REC_0001765 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 15.2 | 65 | male | 1 | 8 | 7.2 | 2 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:57.279257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549211 | REC_0001766 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.9 | 76 | male | 0 | 32 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 35.8 | true | MSS | 2026-03-15T05:35:57.279508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979199 | REC_0001767 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 6.8 | 76 | male | 2 | 18 | 5.8 | 7 | entrectinib 600 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:57.279763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762548 | REC_0001768 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.3 | 68 | male | 0 | 23 | 7.8 | 1 | osimertinib 80 mg daily | 33.4 | false | MSI-H | 2026-03-15T05:35:57.280006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760689 | REC_0001769 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 9.7 | 68 | female | 0 | 0 | 6.5 | 1 | pembrolizumab 200 mg q3w | 34.5 | false | MSS | 2026-03-15T05:35:57.280449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239808 | REC_0001770 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 14.7 | 59 | male | 1 | 23 | 5.5 | 7 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:35:57.280701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385636 | REC_0001771 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 12.8 | 52 | female | 0 | 9 | 3.8 | 4 | sotorasib 960 mg daily | 4.6 | true | MSS | 2026-03-15T05:35:57.280949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267779 | REC_0001772 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 6.4 | 78 | female | 1 | 18 | 4.3 | 2 | pembrolizumab 200 mg q3w | 21.7 | true | MSS | 2026-03-15T05:35:57.281179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175947 | REC_0001773 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 11.1 | 61 | female | 1 | 13 | 6.3 | 1 | sotorasib 960 mg daily | 21.4 | false | MSS | 2026-03-15T05:35:57.281425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328466 | REC_0001774 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 14.5 | 61 | male | 0 | 13 | 4.2 | 8 | pembrolizumab 200 mg q3w | 9.7 | false | MSI-H | 2026-03-15T05:35:57.281679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638637 | REC_0001775 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.5 | 84 | female | 1 | 17 | 3.5 | 6 | sotorasib 960 mg daily | 21 | true | MSI-H | 2026-03-15T05:35:57.281933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200906 | REC_0001776 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10.6 | 75 | female | 2 | 19 | 7.2 | 2 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:35:57.282179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867302 | REC_0001777 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 10.9 | 67 | male | 0 | 28 | 6.3 | 2 | entrectinib 600 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:57.282419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848592 | REC_0001778 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 5.4 | 56 | female | 0 | 36 | 6.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 20 | true | MSS | 2026-03-15T05:35:57.282654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554896 | REC_0001779 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.6 | 59 | female | 1 | 1 | 4.7 | 6 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.282891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591884 | REC_0001780 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.5 | 66 | female | 1 | 54 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.2 | true | MSS | 2026-03-15T05:35:57.283118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164423 | REC_0001781 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.8 | 60 | female | 1 | 8 | 5.2 | 4 | sotorasib 960 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:57.283367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322293 | REC_0001782 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 9.8 | 70 | female | 1 | 24 | 6.2 | 6 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.283745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438339 | REC_0001783 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 11.8 | 66 | female | 1 | 27 | 6 | 4 | entrectinib 600 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:57.284010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970599 | REC_0001784 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 11.8 | 56 | male | 0 | 20 | 5 | 2 | sotorasib 960 mg daily | 21.1 | true | MSS | 2026-03-15T05:35:57.284386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236436 | REC_0001785 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.1 | 69 | female | 0 | 27 | 5.3 | 5 | alectinib 600 mg BID | 15.6 | false | MSS | 2026-03-15T05:35:57.284669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461632 | REC_0001786 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12 | 65 | male | 0 | 14 | 5.2 | 3 | alectinib 600 mg BID | 13.6 | true | MSI-H | 2026-03-15T05:35:57.284940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543003 | REC_0001787 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 10 | 68 | female | 1 | 10 | 4.6 | 3 | pembrolizumab 200 mg q3w | 5.4 | true | MSI-H | 2026-03-15T05:35:57.285223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714155 | REC_0001788 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 13.4 | 65 | female | 0 | 16 | 6.8 | 1 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:57.285479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428175 | REC_0001789 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.7 | 60 | female | 1 | 23 | 4.3 | 5 | alectinib 600 mg BID | 7.2 | false | MSI-H | 2026-03-15T05:35:57.285720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195788 | REC_0001790 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.4 | 64 | male | 1 | 13 | 4.5 | 6 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.285967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778234 | REC_0001791 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.4 | 70 | male | 1 | 10 | 4.7 | 8 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:57.286223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824311 | REC_0001792 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.2 | 75 | female | 0 | 3 | 4.3 | 4 | entrectinib 600 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:57.286484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121437 | REC_0001793 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 14.8 | 55 | female | 1 | 12 | 7 | 5 | sotorasib 960 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.286732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108390 | REC_0001794 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 18 | 13.7 | 62 | female | 1 | 10 | 7.6 | 0 | sotorasib 960 mg daily | 45.4 | true | MSI-H | 2026-03-15T05:35:57.286970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973761 | REC_0001795 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.2 | 56 | female | 1 | 15 | 4.4 | 6 | entrectinib 600 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:57.287359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396645 | REC_0001796 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.3 | 59 | female | 1 | 7 | 7.7 | 2 | alectinib 600 mg BID | 22.9 | false | MSI-H | 2026-03-15T05:35:57.287610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554788 | REC_0001797 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12 | 65 | female | 1 | 18 | 6.3 | 1 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:35:57.287848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292478 | REC_0001798 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9 | 75 | female | 2 | 29 | 5.8 | 3 | osimertinib 80 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:57.288129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464220 | REC_0001799 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.7 | 53 | female | 0 | 14 | 5 | 5 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.288379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657379 | REC_0001800 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 12.6 | 72 | male | 1 | 6 | 5.1 | 8 | pembrolizumab 200 mg q3w | 20.4 | true | MSS | 2026-03-15T05:35:57.288615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.